Topiramate associated non-glaucomatous visual field defects

Haque, Salina; Shaffi, Mohamed; Tang, Kwok Cho

doi:10.1016/j.jocn.2016.03.002

Cited by 5 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Choroidal caverns were first described in eyes with geographic atrophy with an estimated prevalence of 12.5%. 2 Furthermore, this imaging feature has also been described in other ocular disorders, including pachychoroid disease. 3 Importantly, whereas in the study by Dolz-Marco et al 1 only 1 eye showed late hyperfluorescence in the area of the caverns on indocyanine green angiography (ICGA), in the report by Sakurada et al 3 choroidal caverns were hypothesized to represent lipid globules, although caverns were characterized by late hyperfluorescence on ICGA images.…”

mentioning

confidence: 82%

“…Although clearly agreeing with the first definition of glaucomatous VF defect, we wonder whether the second and third definition would be excessive, because the pattern standard deviation has often a P value of <5% and the glaucoma hemifield test result is often outside normal limits also in VFs of individuals without glaucoma. 2,3 In addition, the authors stated that, at the initial evaluation, all patients underwent complete ophthalmologic examinations, including measurement of best-corrected visual acuity, intraocular pressure, central corneal thickness, slit-lamp biomicroscopy, and gonioscopy. They were followed up every 6 months for stereoscopic optic disc and red-free RNFL photography, GC-IPL imaging, and VF testing.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Re: Shin et al.: Patterns of progressive ganglion cell–inner plexiform layer thinning in glaucoma detected by OCT (Ophthalmology. 2018;125:1515-1525)

Grassi

Lim

2019

Ophthalmology

View full text Add to dashboard Cite

This task may prove to be difficult. PPS, which has a molecular structure similar to glycosaminoglycans, is thought to have numerous biological activities. In vitro studies have demonstrated anti-inflammatory, fibrinolytic, and anticoagulant properties among others, with myriad of putative molecular mechanisms. Indeed, the mechanism of action of PPS in interstitial cystitis itself is not wellunderstood. Interestingly, this drug is a proposed therapy for many unrelated diseases. A common theme is that these diseases, including osteoarthritis, CreutzfeldteJakob disease, mucopolysaccharidoses, psychotic disorders, and interstitial cystitis, are notoriously difficult to manage and have limited alternative therapies available.Greenlee et al have identified chronic antagonism of fibroblast growth factor (FGF) signaling as a possible culprit in PPSassociated maculopathy. They note the varied roles FGF signaling plays within the retina, and in particular the importance of FGFdirected injury responses. This line of inquiry will be important. FGF signaling, which involves dozens of FGF subtypes and FGF receptors, serves many roles throughout the body. It is worth exploring whether PPS has other off-target effects outside of the eye related to chronic inhibition of FGF signaling. Further, as suggested by the authors, it will be useful to explore the impact of other FGF antagonists on the health of the retina and the retinal pigment epithelium.Our clinical observations suggest that the primary cellular insult in PPS-associated maculopathy is within the retinal pigment epithelium. We are particularly interested in the resemblance of this condition to various macular dystrophies, which suggests a disruption in normal photoreceptoreretinal pigment epithelium homeostasis. These mechanisms are the subject of our ongoing investigations in the laboratory. This work may in turn lead to greater understanding of diseases such as age-related macular degeneration and macular dystrophies.We hope that our initial observation and thoughtful comments such as those by Greenlee et al will lead to greater understanding of the impact of PPS on the macula, and may ultimately elucidate unanticipated insights into retinal biology. cussion of the limitations of the present study but seek clarification of the points we have raised.

show abstract

mentioning

confidence: 82%

mentioning

confidence: 99%

Re: Shin et al.: Patterns of progressive ganglion cell–inner plexiform layer thinning in glaucoma detected by OCT (Ophthalmology. 2018;125:1515-1525)

Grassi

Lim

2019

Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Additionally, TPM users reportedly experience visual scotomas due to maculopathy and retinal damage. Therefore, when patients are being considered for TPM therapy, baseline perimetry is recommended [ 31 ]. Two case reports of TPM-induced field abnormalities in patients without concomitant ciliochoroidal effusions have been published.…”

Section: Reviewmentioning

confidence: 99%

Section: Visual Field Defectsmentioning

confidence: 99%

The Ophthalmic Side Effects of Topiramate: A Review

Mechrgui¹,

Kanani²

2022

Cureus

View full text Add to dashboard Cite

Topiramate (TPM) is a sulfonamide drug with multiple modes of action. It inhibits carbonic anhydrase, blocks sodium channels, enhances potassium channels, and stimulates postsynaptic gamma-aminobutyric acid (GABA) receptors. Pharmacists Joe Gardocki and Bruce Maryanoff synthesized TPM for the first time in 1979. The FDA did not approve it for medical use in the US until 1996. Around 2004, it was authorized for the prevention of migraine headaches. TPM, like any medication, has several side effects. Common aftermaths include weight loss, diarrhea, dizziness, sleepiness, fatigue, and coordination issues. Some people may experience mental health issues like memory problems, confusion, and speech or language difficulties. The most well-known ocular side effects of TPM are choroidal effusion syndrome, angle-closure glaucoma, and myopic shift. Aside from these, other ophthalmic adverse effects may arise in some people, including retinal problems, uveitis, visual field defects, myokymia, and neuro-ophthalmology complications. If such complications are not identified and treated promptly, they can be severe and vision-threatening, potentially leading to permanent blindness. TPM's application as a standalone and adjunctive therapy has increased over time. In 2019, more than 10 million prescriptions of TPM were issued. Due to its extensive use, medical professionals and patients must be aware of its potential repercussions, especially ophthalmic issues. The current review paper likewise makes a step in this direction. This article's primary purpose is to educate readers by providing a comprehensive assessment of the research on TPM's ocular side effects. All the information has been collected via a thorough search of the Google Search Engine and PubMed.

show abstract

Topiramate

2016

Reactions Weekly

View full text Add to dashboard Cite

Topiramate associated non-glaucomatous visual field defects

Cited by 5 publications

References 7 publications

Re: Shin et al.: Patterns of progressive ganglion cell–inner plexiform layer thinning in glaucoma detected by OCT (Ophthalmology. 2018;125:1515-1525)

Re: Shin et al.: Patterns of progressive ganglion cell–inner plexiform layer thinning in glaucoma detected by OCT (Ophthalmology. 2018;125:1515-1525)

The Ophthalmic Side Effects of Topiramate: A Review

Topiramate

Contact Info

Product

Resources

About